Vertex Pharmaceuticals (VRTX) Projected to Post Quarterly Earnings on Thursday

Vertex Pharmaceuticals (NASDAQ:VRTX) is projected to post its Q4 2025 results after the market closes on Thursday, February 12th. Analysts expect Vertex Pharmaceuticals to post earnings of $5.05 per share and revenue of $3.1762 billion for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 12, 2026 at 4:30 PM ET.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share for the quarter, beating analysts’ consensus estimates of $4.58 by $0.22. The company had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $3.05 billion. Vertex Pharmaceuticals had a return on equity of 23.51% and a net margin of 31.35%.Vertex Pharmaceuticals’s quarterly revenue was up 11.0% on a year-over-year basis. During the same period last year, the firm earned $4.38 earnings per share. On average, analysts expect Vertex Pharmaceuticals to post $16 EPS for the current fiscal year and $18 EPS for the next fiscal year.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX opened at $470.52 on Thursday. The business has a 50-day moving average of $456.21 and a two-hundred day moving average of $427.39. The company has a market capitalization of $119.38 billion, a price-to-earnings ratio of 33.18 and a beta of 0.30. Vertex Pharmaceuticals has a 1 year low of $362.50 and a 1 year high of $519.68.

Insider Activity

In other news, Chairman Jeffrey M. Leiden sold 63,781 shares of the stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $449.20, for a total transaction of $28,650,425.20. Following the completion of the sale, the chairman owned 24,026 shares in the company, valued at approximately $10,792,479.20. This represents a 72.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Ourania Tatsis sold 4,500 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $474.99, for a total value of $2,137,455.00. Following the transaction, the executive vice president directly owned 42,293 shares in the company, valued at approximately $20,088,752.07. This represents a 9.62% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 165,105 shares of company stock valued at $73,858,523. Insiders own 0.20% of the company’s stock.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Invesco Ltd. grew its position in Vertex Pharmaceuticals by 5.7% in the 3rd quarter. Invesco Ltd. now owns 2,096,797 shares of the pharmaceutical company’s stock valued at $821,189,000 after buying an additional 112,751 shares during the last quarter. Lazard Asset Management LLC boosted its holdings in shares of Vertex Pharmaceuticals by 13.4% in the third quarter. Lazard Asset Management LLC now owns 544,823 shares of the pharmaceutical company’s stock valued at $213,374,000 after acquiring an additional 64,513 shares in the last quarter. Raymond James Financial Inc. increased its stake in shares of Vertex Pharmaceuticals by 7.2% during the third quarter. Raymond James Financial Inc. now owns 535,685 shares of the pharmaceutical company’s stock worth $209,796,000 after acquiring an additional 35,908 shares during the period. Bellevue Group AG increased its stake in shares of Vertex Pharmaceuticals by 14.5% during the third quarter. Bellevue Group AG now owns 505,805 shares of the pharmaceutical company’s stock worth $198,093,000 after acquiring an additional 64,195 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its position in Vertex Pharmaceuticals by 520.1% in the third quarter. Arrowstreet Capital Limited Partnership now owns 381,195 shares of the pharmaceutical company’s stock valued at $149,291,000 after purchasing an additional 319,725 shares during the period. 90.96% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently issued reports on VRTX. Barclays raised Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $414.00 to $606.00 in a report on Tuesday, January 27th. Weiss Ratings restated a “hold (c+)” rating on shares of Vertex Pharmaceuticals in a report on Wednesday, January 21st. Royal Bank Of Canada raised shares of Vertex Pharmaceuticals from a “sector perform” rating to an “outperform” rating and increased their target price for the company from $455.00 to $546.00 in a research report on Thursday, January 22nd. Scotiabank began coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $495.00 price target for the company. Finally, JPMorgan Chase & Co. raised their price objective on Vertex Pharmaceuticals from $517.00 to $530.00 and gave the stock an “overweight” rating in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $522.68.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.